(the below program is subject to changes without notice; last updated: February 4, 2020)
Thursday, February 6, 2020
08:45 Welcome
Norbert Krug, Fraunhofer ITEM, Germany
Session 1: Fibrosis
Chair: Antje Prasse, Fraunhofer ITEM
09:00 Validating novel targets for PF-ILDs via differential patient biology
Matthew Thomas, Boehringer Ingelheim (Germany)
09:30 Fibroblast-epithelial cell miscommunication in lung fibrosis
Malgorzata Wygrecka, University of Giessen (Germany)
10:00 Sputum and BAL analysis by chip cytometry following LPS challenge
Saskia Carstensen, Fraunhofer ITEM
10:30 Coffee break
11:00 Fibrosis-specific lung progenitor cells:
role and therapeutic potential in idiopathic pulmonary fibrosis
Katrin Hostettler, University Hospital Basel (Switzerland)
11:30 Advances of in vitro and in vivo models testing epithelial-mesenchymal interaction
Antje Prasse, Fraunhofer ITEM
12:00 The serological evaluation of the extracellular matrix remodeling
and collagen fragments with endocrine properties is important
in both preclinical and clinical evaluation of pulmonary fibrosis
Diana Julie Leeming, Nordic Bioscience (Denmark)
12:30 Lunch
Session 1: Fibrosis (continued)
Chair: Katherina Sewald, Fraunhofer ITEM
13:30 Developing the right preclinical strategy for derisking
anti-fibrotic drug development in pulmonary fibrosis
Simon Cruwys, TherapeutAix (Germany)
14:00 Models of pulmonary hypertension and right heart dysfunction
Soni Pullamsetti, Max Planck Institute (Germany)
14:30 Coffee break
Session 2: COPD and Asthma
Chair: Thomas Tschernig, Saarland University Faculty of Medicine (Germany)
15:00 Effect of cigarette smoke on airway organoids: a model of COPD
Ian Adcock, Imperial College London (UK)
15:30 Advances in treatment of complex lung diseases: targeted therapy with Anticalin molecules
Gabriele Matschiner, Pieris Pharmaceuticals (Germany)
16:00 Unmet medical need in asthma: which drugs are needed for optimal treatment of asthma
J. Christian Virchow, University of Rostock (Germany)
16:30 Wine & cheese poster session
18:00 Keynote lecture
Challenges with the use of animal models for discovery and
development of drugs for the treatment of respiratory diseases
Clive Page, King’s College London (UK)
18:30 Awarding of poster prizes (conference room)
18:45 Guided tours to different non-clinical and clinical departments of Fraunhofer ITEM
19:15 Dinner at the CRC Hannover
21:30 Summary & conclusions day 1
Friday, February 7, 2020
08:25 Guided tours to different non-clinical and clinical departments of Fraunhofer ITEM
Session 3: Infection
Chair: Armin Braun, Fraunhofer ITEM
9:00 Highlights of Fraunhofer iCAIR® – International Consortium for Anti-Infective Research
Jana Führing, Fraunhofer ITEM
9:30 In vivo transcriptional profile of type II pneumocytes in influenza and bacterial (co)infection
Dunja Bruder, Helmholtz Center for Infection Research (Germany) and
Otto-von-Guericke University Magdeburg (Germany)
10:00 Self-DNA sensing in lung inflammatory diseases
Bernhard Ryffel, CNRS – INEM (France)
10:30 Coffee break
11:00 Antibiotics encapsulated in carbohydrate-functionalized nanocarriers
efficiently inhibit mycobacterial propagation in alveolar macrophages
Ulrich Kalinke, TWINCORE (Germany)
11:30 Deciphering the glyco-language of diseases
Daniel Kolarich, Griffith University (Australia)
12:00 Targeting microbial biofilms
Susanne Häußler, TWINCORE (Germany)
12:30 It takes two – understanding host-pathogen interactions using lung tissue infection ex vivo
Sabine Wronski, Fraunhofer ITEM (Germany)
13:00 Lunch
Session 4: Novel technologies
Chair: Jens Hohlfeld, Fraunhofer ITEM
13:45 3D human based models to study lung injury and repair
Melanie Königshoff, University of Colorado, Denver (USA)
14:15 Breath analysis – a critical review
Olaf Holz, Fraunhofer ITEM
14:45 Small-animal imaging in cardiopulmonary diseases
Ralph Schermuly, University of Giessen (Germany)
15:15 The role of glycans in viral and fungal infections studied by NMR spectroscopy
Thomas Haselhorst, Griffith University (Australia)
15:45 End of workshop